New drug duo takes on advanced cancers

NCT ID NCT07131202

Recruiting now Disease control Sponsor: Suzhou Forlong Biotechnology Co., Ltd Source: ClinicalTrials.gov ↗

First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study tests a new drug called FL115 combined with an immunotherapy (PD-1 blocker) in 130 people with advanced solid tumors that have not responded to standard treatments. The trial has two phases: first to find the safest dose, then to see how well the combo works against different tumor types. Participants receive the drugs by IV until their disease gets worse or side effects become too severe.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: FL115 combined with sintilimab (a PD-1 inhibitor)
What this could lead to: If successful, this could point toward a new combination treatment option for people with advanced solid tumors who have run out of standard therapies.
What could go wrong: This is an early-phase trial with only 130 participants, so results may not apply to all patients. The combination may cause side effects or fail to shrink tumors.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ADVANCED SOLID TUMOR are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

neoplasm

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

ADVANCED SOLID TUMORS

Contacts and locations

Locations

Sun Yat-sen University Cancer Center
RECRUITING

Guangzhou, Guangdong, 510000, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.